Clinical trials: Stage II Prostate Cancer
Prostate Cancer
Phase II Study of Pencil Beam Scanning Proton Stereotactic Body Radiation Therapy for Prostate Cancer
This is a single arm phase II study of image-guided pencil beam scanning proton SBRT (40Gy RBE in 5 fractions delivered every other day) for patients with low- and intermediate-risk prostate cancer.
- Trial name
- NCT04842890
- Testing
- Pencil Beam Scanning Proton SBRT
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- The New York Proton Center
Prostate Cancer
A Study of Dovitinib With Androgen Deprivation Therapy (ADT) in Patients With Metastatic Prostate Cancer Receiving Primary ADT
This study will evaluate if adding the investigational drug Dovitinib to standard androgen ablation therapy (ADT) is beneficial in prolonging the time to disease progression in patients with metastatic prostate cancer who are…
- Trial name
- NCT02065323
- Testing
- Standard ADT, Dovitinib
- Where
- United States
- Sponsor
- Oscar Goodman, Jr.
Prostate Cancer (Adenocarcinoma), Metastatic Prostate Cancer
Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate Cancer
To determine if dexamethasone or dexamethasone plus metronidazole restore sensitivity to abiraterone for the treatment of metastatic prostate cancer.
- Trial name
- NCT06616597
- Testing
- Abiraterone acetate, Dexamethasone, Metronidazole
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate Cancer
Salvage Radiotherapy Combined With Hormonotherapy in Oligometastatic Pelvic Node Relapses of Prostate Cancer
There is an increasing number of reports describing the existence of a proportion of prostate cancer patients who present with a reduced number of metastases (<5 lesions) at relapse.
- Trial name
- OLIGOPELVIS (NCT02274779)
- Testing
- ELIGARD
- Where
- 2 sites in France
- Volunteers
- 74 people
- Sponsor
- Institut Cancerologie de l'Ouest
Prostate Cancer
Effects of Two Doses of MPX Capsules on Rising Prostate-specific Antigen Levels in Men Following Initial Therapy for Prostate Cancer
This research is being done to test an investigational product called Muscadine Plus in the treatment of men who have received initial therapy (surgery and or radiation, cryotherapy or brachytherapy) for prostate cancer and are…
- Trial name
- NCT01317199
- Testing
- Muscadine Plus Grape Skin Extract, Low-dose MPX, High-dose MPX
- Where
- 8 sites in United States
- Volunteers
- 143 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostatic Neoplasms
Stereotactic MR-guided Adaptive Radiation Therapy for Localized Prostate Cancer
Rationale: This prospective study investigates the outcomes of daily online stereotactic MR-guided adaptive radiation therapy (SMART) in patients with localized prostate cancer (cT1c-T3bN0M0).
- Trial name
- SMART (NCT03961321)
- Testing
- stereotactic mr guided adaptive radiotherapy
- Where
- Netherlands
- Volunteers
- 104 people
- Sponsor
- Amsterdam UMC, location VUmc
Prostate Adenocarcinoma, Stage IIB Prostate Cancer
Copper Cu 64 TP3805 PET in Detecting Cancer in Patients With Prostate Cancer Undergoing Surgery
This pilot phase I trial studies copper Cu 64 TP3805 (Cu-64-TP3805) positron emission tomography (PET)/computed tomography (CT) in detecting cancer in patients with prostate cancer undergoing surgery to remove the entire prostate…
- Conditions
- Prostate Adenocarcinoma, Stage IIB Prostate Cancer, Stage III Prostate Cancer, Stage IV Prostate Cancer
- Trial name
- NCT02603965
- Testing
- Copper Cu 64 TP3805, Positron Emission Tomography, Computed Tomography
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Prostate Cancer
Biomarkers for Neoadjuvant Pembrolizumab in Non-Metastatic Prostate Cancer Positive by 18FDG-PET Scanning
Various approaches are currently being developed for prostate cancer immunotherapy. However, a major challenge facing the development of cancer immunotherapy is the identification of tumors that would best respond to this type of…
- Trial name
- PICT-01 (NCT04009967)
- Testing
- Pembrolizumab
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- CHU de Quebec-Universite Laval
Prostate Cancer
Celecoxib Compared With No Treatment Before Surgery in Treating Patients With Localized Prostate Cancer
RATIONALE: Celecoxib may be an effective treatment for early stage prostate cancer. It is not yet known if celecoxib is more effective than no treatment before surgery for prostate cancer.
- Trial name
- NCT00022399
- Testing
- celecoxib
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate Cancer
Sbrt±sTad for Unfavorable iNtermediate rIsk/High Risk Prostate caNcer
This is a prospective, open, randomized phase II trial.
- Trial name
- STUNNIN (NCT05557604)
- Testing
- Decapeptyl
- Where
- 3 sites in Italy
- Volunteers
- 146 people
- Sponsor
- Regina Elena Cancer Institute
Breast Cancer, Prostate Cancer
Stereotactic Body Radiation Therapy for Spinal Metastases in Favorite Tumors
Stereotactic Body Radiation Therapy(SBRT) for spinal metastases has been proved a good results in pain relieve and local control, However,the longterm of efficacy and safety of this regimen is unclear.The purpose of the study is…
- Conditions
- Breast Cancer, Prostate Cancer, Non Small Cell Lung Cancer
- Trial name
- NCT03392233
- Testing
- Stereotactic Body Radiation Therapy
- Where
- China
- Volunteers
- 100 people
- Sponsor
- RenJi Hospital
Prostate Cancer
Study of CGC-11047 in Patients With Metastatic Hormone Refractory Prostate Cancer
The purpose of this research is to determine the effectiveness of CGC-11047 in subjects with metastatic hormone refractory prostate cancer as measured by changes in PSA.
- Trial name
- NCT00585416
- Testing
- CGC-11047
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of Wisconsin, Madison
Recurrent or Persistent Localized Carcinoma of the Prostate Following Radiation Therapy Failure
Study of Photodynamic Therapy in Patients With Prostate Cancer Following Radiation Therapy
To assess by MR Imaging the lesions induced by WST09-mediated photodynamic therapy (PDT) in patients with recurrent or persistent localized prostate cancer following definitive radiotherapy using different light doses and…
- Trial name
- NCT00308919
- Testing
- WST09
- Where
- Canada
- Volunteers
- 28 people
- Sponsor
- STEBA France
Prostate Cancer
To Evaluate the Effect of MCS® in Prostate Cancer Prevention
To evaluate the effect of MCS® compared with placebo in reducing the risk of biopsy-detectable prostate cancer in high-risk subjects after 104 weeks (24 months) of treatment.
- Trial name
- MCS-8 (NCT02042807)
- Testing
- MCS®
- Where
- Taiwan
- Volunteers
- 702 people
- Sponsor
- Health Ever Bio-Tech Co., Ltd.
Metastatic Hormone-sensitive Prostate Cancer
A Trial of Immunotherapy Strategies in Metastatic Hormone-sensitive Prostate Cancer
Metastatic prostate cancer is an incurable disease that typically spreads beyond the prostate. The standard of care is to systemically treat the disease with androgen deprivation therapy (ADT).
- Trial name
- NCT03879122
- Testing
- Ipilimumab 5 MG/ML, Nivolumab 10 MG/ML, Docetaxel
- Where
- 30 sites in Spain
- Volunteers
- 135 people
- Sponsor
- Spanish Oncology Genito-Urinary Group
Adenocarcinoma of the Prostate
TOPARP: A Phase II Trial of Olaparib in Patients With Advanced Castration Resistant Prostate Cancer
This is an open-label, single arm, two part adaptive design phase II trial of Olaparib in patients with advanced castration resistant prostate cancer.
- Trial name
- TOPARP (NCT01682772)
- Testing
- Olaparib
- Where
- 2 sites in United Kingdom
- Volunteers
- 148 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Prostate Cancer
Abiraterone, Radiotherapy and Short-Term Androgen Deprivation in Unfavorable Localized Prostate Cancer
The addition of abiraterone acetate to standard treatment of radiotherapy and short-term androgen deprivation will increase the frequency of undetectable PSA.
- Trial name
- NCT01717053
- Testing
- Abiraterone acetate, Androgen deprivation, Radiation Therapy
- Where
- 3 sites in United States
- Volunteers
- 37 people
- Sponsor
- Duke University
Recurrent Prostate Cancer
Phase II Study of Adenovirus/PSA Vaccine in Men With Recurrent Prostate Cancer After Local Therapy APP21
The purpose of this study is to determine whether vaccination with the Ad/PSA vaccine will induce an anti-PSA immunity that will result in the destruction of the remaining prostate cancer cells.
- Trial name
- APP21 (NCT00583752)
- Testing
- Adenovirus/PSA Vaccine
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- David M Lubaroff
Metastatic Prostate Cancer
Low Dose Naltrexone (LDN) for Management of Fatigue in Prostate Cancer Patients on Androgen Deprivation Therapy (ADT)
The study is being done to see if a small daily dose of naltrexone (LDN, 3 mg pill) can help reduce tiredness (fatigue) in men with prostate cancer.
- Trial name
- NCT07224009
- Testing
- Naltrexone
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Arkansas
Prostatic Neoplasms, Neoplasms, Hormone-Dependent
An Open-label Phase II Study With SUTENT in Patients Suffering From Hormone Refractory Prostate Cancer
as second-line treatment in metastatic prostate cancer, the present study will investigate the efficacy of sunitinib (SUTENT) given orally at a dose of 37.5 mg continuously, for 6 cycles of 6 consecutive weeks .Patients who are…
- Conditions
- Prostatic Neoplasms, Neoplasms, Hormone-Dependent, Tumor Markers, Biological, Survival Rate
- Trial name
- PROSUT (NCT00748358)
- Testing
- sunitinib
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris